Author

H. A. Katus

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

N. Frey· 3 shared A. Jungmann· 2 shared D. Kehr· 2 shared E. Gao· 2 shared J. Birkenstock· 2 shared J. Ritterhoff· 2 shared K. Varadi· 2 shared P. Most· 2 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

N. Frey

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CXCL4-induced PBMCs Modulate Vascular Extracellular Matrix through Wnt5a-dependent Release of Calcific Extracellular Vesicles and Matrix Metalloproteinase-7

J. B. Krohn, F. Sicklinger, A. Spieler, S. Dihlmann, C. A. Gleissner, H. A. Katus, N. Frey, F. Leuschner

This study identifies a novel mechanism by which CXCL4-induced monocytes release calcific extracellular vesicles and MMP7 to modulate vascular extracellular matrix through Wnt5a-CaMKII signaling.

bioRxiv · May 15, 2023 · PreprintImmunology

S100A1ct: a synthetic peptide derived from human S100A1 protein improves cardiac contractile performance and survival in pre-clinical heart failure models

D. Kehr, J. Ritterhoff, M. Glaser, L. Jarosch, R. Salazar, K. Spaich, K. Varadi, J. Birkenstock, M. Egger, E. Gao, W. J. Koch, H. A. Katus, N. Frey, A. Jungmann, C. Busch, , P. Most

This paper develops a synthetic peptide S100A1ct that improves cardiac function and survival in heart failure models by enhancing Ca2+ cycling and targeting SERCA2a and RyR2.

bioRxiv · Mar 4, 2023Pharmacology & Toxicology

Cardiac-targeted rAAV5-S100A1 gene therapy protects against adverse remodeling and contractile dysfunction in post-ischemic hearts

D. Kehr, J. Salatzki, B. Krautz, K. Varadi, J. Birkenstock, P. Schlegel, E. Gao, W. J. Koch, J. Riffel, F. Andre, K. Peppel, H. A. Katus, N. Frey, M. Busch, H. Pfannkuche, , P. Most

This study demonstrates that cardiac-targeted rAAV5-S100A1 gene therapy reduces adverse remodeling and improves contractile function in post-ischemic hearts in pigs and mice.

bioRxiv · Mar 3, 2023 · PreprintPathology